Home › NDC Lookup › RxCUI directory › RxCUI 2359290

24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extende... — RxCUI 2359290

Name: 24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Ex… (RxCUI 2359290)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2359290 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2359290

Official name24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Trijardy]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asTrijardy XR (empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin HCl 1000 MG) 24HR Extended Release Oral Tablet; Trijardy XR 12.5 MG / 2.5 MG / 1000 MG 24HR Extended Release Oral Tablet

FDA products mapped4

Package NDCs mapped8

Reported Medicaid activity (SDUD)29,523 prescriptions · 17 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Linagliptin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It helps lower blood sugar in adults with type 2 diabetes, alongside diet and exercise. It is not meant for type 1 diabetes, where it would not work.
Take one tablet by mouth once a day. You can take it with or without food. Follow your prescriber's directions and the label on your prescription.
Common ones are a stuffy or runny nose, sore throat, diarrhea and cough. Other effects depend on what you take with it, such as urinary tract infections with a sulfonylurea or cons...
Call for severe stomach pain that won't go away, which could be pancreatitis. Also call for swelling of the face or throat, hives, blisters, severe joint pain, or heart failure sig...

📖 Read our full Linagliptin guide →

🕸️ Concept Web — How 24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet [Trijardy] RxCUI 2359290 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 5

The active substance itself — no strength, form, or brand attached yet.
- Empagliflozin 1545653 IN
- Linagliptin 1100699 IN
- Metformin 6809 IN
- Empagliflozin / linagliptin / metformin 2281864 MIN
- Metformin hydrochloride 235743 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Trijardy 2359280 BN
Dose forms 13

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Empagliflozin / linagliptin / metformin Extended Release Oral Tablet 2359278 SCDF
- Empagliflozin / linagliptin / metformin hydrochloride Extended Release Oral Tablet 2646947 SCDFP
- Empagliflozin / linagliptin / metformin Oral Product 2359276 SCDG
- Empagliflozin / linagliptin / metformin Pill 2359277 SCDG
- Empagliflozin / linagliptin / metformin hydrochloride Oral Product 2663153 SCDGP
- Empagliflozin / linagliptin / metformin hydrochloride Pill 2661199 SCDGP
- Empagliflozin / linagliptin / metformin Extended Release Oral Tablet [Trijardy] 2359282 SBDF
- Empagliflozin / linagliptin / metformin hydrochloride Extended Release Oral Tablet [Trijardy] 2658588 SBDFP
- +5 more in this family
Clinical & branded drugs 5

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet 2359288 SCD
- Empagliflozin 12.5 MG 1664322 SCDC
- Linagliptin 2.5 MG 1243015 SCDC
- Metformin hydrochloride 1000 MG 860995 SCDC
- Empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG [Trijardy] 2359289 SBDC

Showing up to 8 concepts per family — 19 of 24 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

24 HR empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG Extended Release Oral Tablet SCD · 2359288
Empagliflozin 12.5 MG SCDC · 1664322
Linagliptin 2.5 MG SCDC · 1243015
Metformin hydrochloride 1000 MG SCDC · 860995
Empagliflozin / linagliptin / metformin Extended Release Oral Tablet SCDF · 2359278
Empagliflozin / linagliptin / metformin hydrochloride Extended Release Oral Tablet SCDFP · 2646947
Empagliflozin / linagliptin / metformin Oral Product SCDG · 2359276
Empagliflozin / linagliptin / metformin Pill SCDG · 2359277
Empagliflozin / linagliptin / metformin hydrochloride Oral Product SCDGP · 2663153
Empagliflozin / linagliptin / metformin hydrochloride Pill SCDGP · 2661199

Brand-Name Concepts

Empagliflozin 12.5 MG / linagliptin 2.5 MG / metformin hydrochloride 1000 MG [Trijardy] SBDC · 2359289
Empagliflozin / linagliptin / metformin Extended Release Oral Tablet [Trijardy] SBDF · 2359282
Empagliflozin / linagliptin / metformin hydrochloride Extended Release Oral Tablet [Trijardy] SBDFP · 2658588
Trijardy Oral Product SBDG · 2359283
Trijardy Pill SBDG · 2359284
Trijardy BN · 2359280

📦 FDA Products & Package NDCs

4 products · 8 package NDCs

8 package NDCs map to RxCUI 2359290 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00597-0380-13	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-13)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0380-68	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-68)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0385-77	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-77)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0385-86	180 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-86)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0390-13	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-13)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0390-71	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0395-23	180 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0395-23)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23
00597-0395-82	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0395-82)	Trijardy XR	Boehringer Ingelheim Pharmaceuticals, Inc.	2020-04-23

Observed labelers: Boehringer Ingelheim Pharmaceuticals, Inc. (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.